Table 2. Allelic loss of XPC occurs in the majority of human SCLC and NSCLC tumors, whereas allelic loss of Gadd45a occurs in various tumor types
Marker/gene Location/distance Allelic loss Ref.
D3S1263 3/11,492 100% in 14 SCLC, 41% in 22 NSCLC 16
D3S1263 3/11,492 54% of 79 NSCLC 15
XPC 3/14,178
D3S2338 3/16,824 89% in 14 SCLC, 58% in 22 NSCLC 16
D3S2338 3/16,824 53% in 79 NSCLC 15
D3S1263 or D3S2338* 100% in 14 SCLC, 73% of 22 NSCLC 16
D3S1263 and D3S2338* 89% in 14 SCLC, 41% of 22 NSCLC 16
D3S1263 or D3S2338* 75% of 79 NSCLC 15
D3S1263 and D3S2338* 35% of 79 NSCLC 15
D1S209 1/61,342 16% of 471 tumors (various tissues) 18
D1S230 1/61,972 0% in 14 SCLC, 59% in 22 NSCLC 16
Gadd45a 1/67,522
D1S2829 1/67,622 42% in 38 ovarian and breast tumors 17
D1S216 1/77,078 17% in 342 tumors (various tissues) 18
D1S2841 1/78,910 0% in 14 SCLC, 43% in 22 NSCLC 16
  • Published data were extended to include XPC and Gadd45a genes. Location is designated as chromosome no./distance from telomere (in kbp). Distance from telomere was obtained from www.ncbi.nih.gov/mapview or http://genome.ucsc.edu.

  • * Potential XPC allelic loss in two independent studies. Allelic loss of either flanking marker indicating potential XPC loss, or of both flanking makers indicating near certain XPC loss